Is Lithium Still First-Line for Bipolar Disorder?
Yes, lithium remains a first-line treatment for bipolar disorder in adults, particularly for maintenance therapy and prevention of manic episodes. The FDA approves lithium for treating acute manic episodes and as maintenance therapy to reduce the frequency and intensity of manic episodes 1. Multiple recent systematic reviews and expert consensus papers from 2018-2024 consistently reaffirm lithium as the "gold standard" for long-term management of bipolar disorder 2, 3, 4, 5.
Evidence Supporting First-Line Status
Lithium demonstrates the strongest evidence base for:
- Maintenance/prophylactic treatment - This is where lithium excels most robustly, with all clinical practice guidelines recommending it as first-line for preventing mood episode recurrence 6
- Acute mania treatment - Strong support across guidelines, though often used with adjunctive medications 6
- Suicide prevention - Unique among mood stabilizers with tangible reduction in suicide risk across all guidelines 6
The 2017 synthesis of international clinical practice guidelines confirms lithium as the most robustly supported first-line intervention for maintenance treatment, with strong support for acute mania and modest support for bipolar depression 6.
The Clinical Reality Gap
Despite being scientifically established as most efficacious, lithium prescription has declined to approximately 35% or less of bipolar disorder patients internationally 2. This represents a troubling disconnect between evidence and practice. A 2024 review argues that "decades of scientific investigations and education...has not increased the use of lithium on a population-based large scale" 2.
Practical Treatment Algorithm
For newly diagnosed bipolar disorder:
- Start with lithium for acute mania (with atypical antipsychotic if needed for rapid control)
- Taper the antipsychotic once remission achieved during continuation treatment
- Continue lithium monotherapy for long-term prophylaxis 5
Target therapeutic levels:
- Standard adults: 0.6-0.8 mmol/L for maintenance 6
- Ages 60-79: 0.4-0.8 mmol/L 7, 8
- Age 80+: 0.4-0.7 mmol/L 7, 8
Critical Monitoring Requirements
Before initiating:
- Baseline renal function (creatinine, eGFR)
- Thyroid function (TSH, free T4)
- Pregnancy test in women of childbearing age
- ECG in patients >50 or with cardiac risk factors
During treatment:
- Lithium levels: weekly until stable, then every 3-6 months
- Renal function: every 6-12 months
- Thyroid function: every 6-12 months
- Watch for polyuria/polydipsia (early sign of nephrogenic diabetes insipidus)
Common Pitfalls and Management
Drug interactions requiring dose adjustment or closer monitoring:
- Diuretics - reduce renal lithium clearance, increase toxicity risk 1
- ACE inhibitors/ARBs - same mechanism as diuretics 1
- NSAIDs - can increase lithium levels by 17% or more; indomethacin and piroxicam particularly problematic 1
Maintain adequate hydration (2500-3000 mL daily) and normal salt intake - sodium depletion increases lithium retention and toxicity risk 1.
Early toxicity signs requiring immediate discontinuation and physician contact:
- Diarrhea, vomiting
- Tremor, mild ataxia
- Drowsiness, muscular weakness 1
Special Populations
Pregnancy (Category D): Lithium carries teratogenic risk and should generally be avoided, though risk-benefit may favor continuation in severe cases 1. The combination of olanzapine-fluoxetine is FDA-approved for bipolar depression in adults as an alternative 9.
Older adults: Age-related reduction in renal clearance necessitates lower therapeutic targets. Recent evidence strongly supports age-specific ranges, though many laboratories still don't report them 7, 8.
Renal/cardiovascular disease: Generally contraindicated due to very high toxicity risk unless psychiatric indication is life-threatening 1.
When to Consider Alternatives First
Lithium may not be first choice when:
- Significant renal impairment exists
- Severe cardiovascular disease present
- Patient unable to maintain adequate hydration
- Rapid cycling pattern (valproate may be preferable)
- Predominant bipolar depression (lamotrigine consideration)
- Patient preference after informed discussion of risks/benefits
The Delay Problem
A 2026 case register study found a median delay of 659 days between first mental health assessment and lithium initiation, with patients experiencing a median of 2.5 mood episodes and trying 2 antipsychotics before receiving lithium 10. This delay is clinically unjustified given lithium's evidence base and should be actively avoided.
The evidence overwhelmingly supports earlier, not later, lithium initiation for appropriate candidates with bipolar disorder 2, 5. The declining use represents a failure to translate evidence into practice, not a reflection of lithium's efficacy or safety profile when properly managed.